Efficacy of once‐daily glucagon‐like peptide‐1 receptor agonist lixisenatide as an add‐on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual‐level pooled analysis of phase III studies

Efficacy of once‐daily glucagon‐like peptide‐1 receptor agonist lixisenatide as an add‐on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual‐level pooled analysis of phase III studies

Abstract Aims/Introduction The prevalence and pathophysiological background of type 2 diabetes mellitus vary across ethnicities, and can affect treatment responses. Adding lixisenatide to basal insulin (BI) in type 2 diabetes mellitus patients has shown improvements in glycated hemoglobin (HbA1c) an...

Full description

Bibliographic Details
Main Authors: Fuqiang Liu, Yuan Liu, Minzhi Liu, Guangyu Wu, Minlu Zhang, Xia Zhang, Nan Cui, Huiqiu Yin, Li Chen
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:Journal of Diabetes Investigation
Subjects:
Glucagon‐like peptide‐1 receptor agonist
Lixisenatide
Pooled analysis
Online Access:https://doi.org/10.1111/jdi.13504

Internet

https://doi.org/10.1111/jdi.13504

Similar Items